prednisolone has been researched along with Hemophilia B in 9 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Hemophilia B: A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind controlled study was carried out to investigate the effectiveness of treatment with factor VIII or factor IX concentrate and a reducing dose of prednisolone in contolling haematuria in patients with haemophilia and Christmas disease." | 9.04 | A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease. ( Kernoff, PB; Matthews, JM; McLennan, CR; Rainsford, SG; Rizza, CR, 1977) |
| "A 31-year-old man with mild hemophilia B developed a herniated disc treated with prednisolone for back pain." | 7.91 | Prednisolone treatment induced temporary factor IX normalization in mild hemophilia B who required an epidural infiltration: A case report. ( Barbay, V; Billoir, P; Carrette, M; Chamouni, P; Feugray, G; Fretigny, M; Le Cam Duchez, V, 2019) |
| "A double-blind controlled study was carried out to investigate the effectiveness of treatment with factor VIII or factor IX concentrate and a reducing dose of prednisolone in contolling haematuria in patients with haemophilia and Christmas disease." | 5.04 | A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease. ( Kernoff, PB; Matthews, JM; McLennan, CR; Rainsford, SG; Rizza, CR, 1977) |
| "A 31-year-old man with mild hemophilia B developed a herniated disc treated with prednisolone for back pain." | 3.91 | Prednisolone treatment induced temporary factor IX normalization in mild hemophilia B who required an epidural infiltration: A case report. ( Barbay, V; Billoir, P; Carrette, M; Chamouni, P; Feugray, G; Fretigny, M; Le Cam Duchez, V, 2019) |
| " He also had troublesome psoriasis for which he was receiving acitretin with UVB therapy and had recently discontinued low-dose daily prednisolone for associated arthropathy." | 3.69 | Multiple dermatofibromas in a patient with HIV infection. ( Armstrong, DK; Burrows, D; Irvine, A; Mayne, EE; Walsh, MY, 1995) |
| "The bleeding was effectively controlled within 1 to 48 h in five of nine bleeding episodes." | 2.69 | Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. ( Angchaisuksiri, P; Chuansumrit, A; Hathirat, P; Isarangkura, P; Jorgensen, LN; Sriudomporn, N; Tanpowpong, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chandrakumara, J | 1 |
| Wijesundara, M | 1 |
| Amarakoon, G | 1 |
| Miesbach, W | 1 |
| Meijer, K | 1 |
| Coppens, M | 1 |
| Kampmann, P | 1 |
| Klamroth, R | 1 |
| Schutgens, R | 1 |
| Tangelder, M | 1 |
| Castaman, G | 1 |
| Schwäble, J | 1 |
| Bonig, H | 1 |
| Seifried, E | 1 |
| Cattaneo, F | 1 |
| Meyer, C | 1 |
| Leebeek, FWG | 1 |
| Carrette, M | 1 |
| Feugray, G | 1 |
| Chamouni, P | 1 |
| Le Cam Duchez, V | 1 |
| Fretigny, M | 1 |
| Barbay, V | 1 |
| Billoir, P | 1 |
| Egorova, LV | 1 |
| Papaian, LP | 1 |
| Khrolova, PV | 1 |
| Volkova, SD | 1 |
| Fedorova, ZD | 1 |
| Armstrong, DK | 1 |
| Irvine, A | 1 |
| Walsh, MY | 1 |
| Mayne, EE | 1 |
| Burrows, D | 1 |
| Chuansumrit, A | 1 |
| Isarangkura, P | 1 |
| Angchaisuksiri, P | 1 |
| Sriudomporn, N | 1 |
| Tanpowpong, K | 1 |
| Hathirat, P | 1 |
| Jorgensen, LN | 1 |
| Rizza, CR | 1 |
| Kernoff, PB | 1 |
| Matthews, JM | 1 |
| McLennan, CR | 1 |
| Rainsford, SG | 1 |
| Schimpf, K | 1 |
| Handley, DA | 1 |
| Lawrence, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II, Open-label, Uncontrolled, Single-dose, Dose-ascending, Multi-centre Trial Investigating an Adeno-associated Viral Vector Containing a Codon-optimized Human Factor IX Gene (AAV5-hFIX) Administered to Adult Patients With Severe or Moderately S[NCT02396342] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2015-06-10 | Completed | ||
| A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)[NCT06114056] | Phase 1 | 6 participants (Anticipated) | Interventional | 2023-11-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02396342)
Timeframe: From AMT-060 infusion through end of study (5 years post-dose)
| Intervention | participants (Number) |
|---|---|
| AAV5-hFIX Low Dose (Cohort 1) | 5 |
| AAV5-hFIX High Dose (Cohort 2) | 5 |
(NCT02396342)
Timeframe: From AMT-060 infusion through end of study (5 years post dose)
| Intervention | participants (Number) |
|---|---|
| AAV5-hFIX Low Dose (Cohort 1) | 5 |
| AAV5-hFIX High Dose (Cohort 2) | 5 |
Specific AAV5 response (results >17 SFC/million PBMCs) were regarded as positive. (NCT02396342)
Timeframe: From AMT-060 infusion through 26 weeks post-dose
| Intervention | participants (Number) |
|---|---|
| AAV5-hFIX Low Dose (Cohort 1) | 1 |
| AAV5-hFIX High Dose (Cohort 2) | 0 |
(NCT02396342)
Timeframe: From AMT-060 infusion through the end of study (5 years post dose)
| Intervention | participants (Number) |
|---|---|
| AAV5-hFIX Low Dose (Cohort 1) | 1 |
| AAV5-hFIX High Dose (Cohort 2) | 0 |
(NCT02396342)
Timeframe: From AMT-060 infusion through 18 weeks post dose
| Intervention | participants (Number) |
|---|---|
| AAV5-hFIX Low Dose (Cohort 1) | 0 |
| AAV5-hFIX High Dose (Cohort 2) | 0 |
(NCT02396342)
Timeframe: From AMT-060 infusion through the end of study (5 years post dose)
| Intervention | participants (Number) |
|---|---|
| AAV5-hFIX Low Dose (Cohort 1) | 0 |
| AAV5-hFIX High Dose (Cohort 2) | 0 |
Scores range from 0 to 100, with a higher score defining a more favorable health state. (NCT02396342)
Timeframe: From AMT-060 infusion through the end of study (5 years post dose)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Role-Physical | Bodily Pain | General Health | Vitality | Social Functioning | Role-Emotional | Mental Health | |
| AAV5-hFIX High Dose (Cohort 2) | -7.00 | -10.00 | 1.20 | -2.40 | -6.25 | -5.00 | -10.00 | -9.00 |
| AAV5-hFIX Low Dose (Cohort 1) | 0.00 | -15.00 | -9.00 | -0.80 | -11.25 | -20.00 | -13.33 | -13.00 |
FIX activity measured any time from 72 hours after latest FIX replacement therapy administration and until next administration of FIX replacement therapy. Only assessments performed more than 10 days after most recent FIX-replacement therapy administration included. (NCT02396342)
Timeframe: From AMT-060 infusion through end of study (5 years post-dose)
| Intervention | Percent FIX activity (Mean) | |
|---|---|---|
| one-stage aPTT assay | amidolytic/chromogenic assay | |
| AAV5-hFIX High Dose (Cohort 2) | 6.60 | 4.74 |
| AAV5-hFIX Low Dose (Cohort 1) | 7.43 | 4.58 |
(NCT02396342)
Timeframe: From AMT-060 infusion through end of study (5 years post dose).
| Intervention | Days (Mean) | |||||
|---|---|---|---|---|---|---|
| Blood | Nasal secretions | Saliva | Urine | Feces | Semen | |
| AAV5-hFIX High Dose (Cohort 2) | 705.4 | 108.4 | 129.2 | 82.0 | 165.0 | 157.2 |
| AAV5-hFIX Low Dose (Cohort 1) | 508.8 | 83.4 | 75.8 | 46.4 | 74.0 | 227.8 |
Annualized: Sum of post-treatment bleeding episodes divided by subjects' average number of years (365.25 days) from treatment start to until the data cutoff date. (NCT02396342)
Timeframe: From AMT-060 infusion through end of study (5 years post-dose)
| Intervention | bleeds/year/subject (Mean) | |
|---|---|---|
| One Year Prior to Screening | Post-tapering Period | |
| AAV5-hFIX High Dose (Cohort 2) | 4.00 | 0.71 |
| AAV5-hFIX Low Dose (Cohort 1) | 14.40 | 5.39 |
(NCT02396342)
Timeframe: From AMT-060 infusion through end of study (5 years post dose).
| Intervention | IU (Mean) | |
|---|---|---|
| One year prior to screening | Post-tapering period | |
| AAV5-hFIX High Dose (Cohort 2) | 233778 | 85800 |
| AAV5-hFIX Low Dose (Cohort 1) | 326532 | 252950 |
For subjects with a titer of 109350 and 50, the actual titer is >109350 and <50. (NCT02396342)
Timeframe: AMT-060 infusion through end of study (5 years post dose)
| Intervention | Titer (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| IgG (subject 1) | IgG (subject 2) | IgG (subject 3) | IgG (subject 4) | IgG (subject 5) | IgM (subject 1) | IgM (subject 2) | IgM (subject 3) | IgM (subject 4) | IgM (subject 5) | |
| AAV5-hFIX High Dose (Cohort 2) | 109350 | 109350 | 109350 | 107344 | 109350 | 30071 | 20000 | 6649 | 50 | 50 |
| AAV5-hFIX Low Dose (Cohort 1) | 79499 | 109350 | 109350 | 109350 | 109350 | 56 | 1321 | 557 | 11568 | 809 |
3 trials available for prednisolone and Hemophilia B
| Article | Year |
|---|---|
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Topics: Adult; Dependovirus; Factor IX; Female; Genetic Therapy; Genetic Vectors; Hemophilia B; Humans; Male | 2018 |
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Topics: Adult; Dependovirus; Factor IX; Female; Genetic Therapy; Genetic Vectors; Hemophilia B; Humans; Male | 2018 |
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Topics: Adult; Dependovirus; Factor IX; Female; Genetic Therapy; Genetic Vectors; Hemophilia B; Humans; Male | 2018 |
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Topics: Adult; Dependovirus; Factor IX; Female; Genetic Therapy; Genetic Vectors; Hemophilia B; Humans; Male | 2018 |
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Child, Preschool; Disease Management; Fact | 2000 |
A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Factor IX; Factor VIII; Hematuria; Hemophilia A | 1977 |
6 other studies available for prednisolone and Hemophilia B
| Article | Year |
|---|---|
A child diagnosed with severe hemophilia A presenting with nephrotic syndrome: a case report.
Topics: Child; Factor VIII; Hemophilia A; Hemophilia B; Humans; Male; Nephrotic Syndrome; Prednisolone | 2023 |
Prednisolone treatment induced temporary factor IX normalization in mild hemophilia B who required an epidural infiltration: A case report.
Topics: Adult; Factor IX; Hemophilia B; Humans; Intervertebral Disc Displacement; Male; Partial Thromboplast | 2019 |
[Hormone therapy of renal hemorrhages in hemophiliacs].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Hematuria; Hemophilia A; Hemophilia B; Hemorrhage; Human | 1982 |
Multiple dermatofibromas in a patient with HIV infection.
Topics: Acitretin; Adult; Hemophilia B; Histiocytoma, Benign Fibrous; HIV Infections; Humans; Male; Predniso | 1995 |
[Substitution treatment in hemophilia. Critical measures and complications].
Topics: Blood Transfusion; Disseminated Intravascular Coagulation; Factor IX; Factor VIII; Half-Life; Hemoph | 1977 |
Factor-IX deficiency in the nephrotic syndrome.
Topics: Adolescent; Biological Assay; Blood Coagulation Tests; Child; Hemophilia B; Humans; Male; Nephrotic | 1967 |